Dentzer James E

SEC source: 0001437749-26-025667 · rdgdoc.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,897

F1 · shares: Stock granted in lieu of cash for portion of board fees

SEC source: 0001108205-26-000089 · wk-form4_1783627759.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,090

Underlying: Common Stock · 110,090 shares

Expires 2036-07-06

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on July 7, 2027 and as to an additional 6.25% of the original shares each successive quarter and until July 7, 2030.

SEC source: 0001437749-26-018549 · rdgdoc.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,963

F1 · shares: Stock granted in lieu of cash for portion of board fees

SEC source: 0001108205-26-000037 · wk-form4_1774296187.xml · derivative · entry 2

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 133,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F1 · price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F1 · derivative.exercise_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F1 · derivative.expiration_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

SEC source: 0001108205-26-000037 · wk-form4_1774296187.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

SEC source: 0001108205-26-000025 · wk-form4_1773865277.xml · derivative · entry 4

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,333

Underlying: Common Stock · 133,333 shares

Expires 2027-07-08

F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F5 · derivative.exercise_date: The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026.

SEC source: 0001108205-26-000025 · wk-form4_1773865277.xml · derivative · entry 3

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,333

Underlying: Common Stock · 133,333 shares

Expires not disclosed

F4 · derivative.exercise_price: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.

F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F4 · derivative.exercise_date: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.

F4 · derivative.expiration_date: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.

SEC source: 0001108205-26-000025 · wk-form4_1773865277.xml · derivative · entry 2

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,333

Underlying: Common Stock · 133,333 shares

Expires 2031-01-08

F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F3 · derivative.exercise_date: Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026.

SEC source: 0001108205-26-000025 · wk-form4_1773865277.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100

Underlying: Common Stock · 100 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).

F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

F1 · derivative.exercise_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).

F1 · derivative.expiration_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).

SEC source: 0001437749-26-000606 · rdgdoc.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,405

Underlying: Common Stock · 4,405 shares

Expires 2036-01-02

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001437749-25-025102 · rdgdoc.xml · derivative · entry 2

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250

Underlying: Common Stock · 250 shares

Expires 2035-08-04

F2 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F3 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001437749-25-025102 · rdgdoc.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,318

F1 · shares: Stock granted in lieu of cash for portion of board fees

SEC source: 0001108205-25-000069 · wk-form4_1747944826.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,000

Underlying: Common Stock · 360,000 shares

Expires 2035-01-27

F1 · date: This option grant, as disclosed in Curis Inc.'s 2025 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 28, 2025, contingent upon shareholder approval of Curis's Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if Amendment No. 1 to the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 20, 2025, at the 2025 annual meeting of shareholders, Curis's shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Plan.

F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2026 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2029.

SEC source: 0001437749-25-008263 · rdgdoc.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common Stock · 3,750 shares

Expires 2035-03-14

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001108205-25-000016 · wk-form4_1738271402.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-01-27

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2026 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2029.

SEC source: 0001437749-24-028881 · rdgdoc.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,301

Underlying: Common Stock · 3,634 shares

Expires 2034-09-06

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F3 · shares: Option granted in lieu of cash for portion of board fees.

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001437749-24-020254 · rdgdoc.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,667

Underlying: Common Stock · 4,500 shares

Expires 2034-06-12

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001108205-24-000054 · wk-form4_1716495080.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-01-18

F1 · date: This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 19, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to, among other things, increase the number of shares authorized for issuance thereunder and increase the per participant limit on the number of shares subject to awards that can be granted annually to participants in the plan; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan.

F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 19, 2025 and as to an additional 6.25% of the original shares each successive quarter and until January 19, 2028.

SEC source: 0001437749-24-008330 · rdgdoc.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,167

Underlying: Common Stock · 4,500 shares

Expires 2034-03-15

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001437749-23-007407 · rdgdoc.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,667

Underlying: Common Stock · 2,000 shares

Expires 2033-03-17

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/3 on the date of grant; 1/3 on the on the one year anniversary of the date of grant; and 1/3 on the second year anniversary of the date of grant.

SEC source: 0001108205-23-000009 · wf-form4_167459427200965.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2033-01-19

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 20, 2024 and as to an additional 6.25% of the original shares each successive quarter and until January 20, 2027.

SEC source: 0001062993-22-020170 · form4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,667

Underlying: Common Stock · 2,667 shares

Expires 2032-09-30

F1 · derivative.exercise_date: Represents an option grant under the Issuer's 2018 Stock Plan. The option vests in equal installments commencing January 1, 2023 and annually thereafter.

SEC source: 0001209191-22-005651 · doc4.xml · nonDerivative · entry 2

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,877

F2 · kind: This transaction was effected pursuant to Rule 10b5-1 trading plans to cover tax obligations.

SEC source: 0001209191-22-005651 · doc4.xml · derivative · entry 3

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 825,000

Underlying: Common stock · 825,000 shares

Expires 2032-01-28

F3 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 29, 2023 and as to an additional 6.25% of the original shares each successive quarter and until January 29, 2026.

SEC source: 0001209191-22-005651 · doc4.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,971

F1 · kind: Shares were sold pursuant to a "sell to cover" arrangement to satisfy minimum statutory tax withholding obligations related to a vesting of a service-based restricted stock award granted on January 22, 2018.

SEC source: 0001209191-21-006098 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,000

Underlying: Common stock · 330,000 shares

Expires 2031-01-27

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2022 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2025.

SEC source: 0001209191-21-005492 · doc4.xml · nonDerivative · entry 2

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,268

F2 · kind: This transaction was effected pursuant to Rule 10b5-1 trading plans to cover tax obligations.

SEC source: 0001209191-21-005492 · doc4.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,362

F1 · kind: Shares were sold pursuant to a "sell to cover" arrangement to satisfy minimum statutory tax withholding obligations related to a vesting of a service-based restricted stock award granted on January 22, 2018.

SEC source: 0001209191-20-016227 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common stock · 750,000 shares

Expires 2030-03-01

F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on March 2, 2021 and as to an additional 6.25% of the original shares each successive quarter and until March 2, 2024.

SEC source: 0001209191-20-004918 · doc4.xml · nonDerivative · entry 2

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,158

F2 · kind: This transaction was effected pursuant to Rule 10b5-1 trading plans to cover tax obligations.

SEC source: 0001209191-20-004918 · doc4.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,252

F1 · shares: Shares were sold pursuant to a "sell to cover" arrangement to satisfy minimum statutory tax withholding obligations related to a vesting of a service-based restricted stock award granted on January 22, 2018.

SEC source: 0001209191-19-032974 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,115,871

Underlying: Common Stock · 1,115,871 shares

Expires 2029-01-20

F1 · date: This option grant, as disclosed in Curis Inc.'s 2019 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 21, 2019, contingent upon shareholder approval of an amendment to Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the amendment to the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 23, 2019, at the 2019 annual meeting of shareholders, Curis's shareholders approved the amendment to the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 21, 2020 and as to an additional 6.25% of the original shares each successive quarter and until January 21, 2023.

F1 · derivative.exercise_date: This option grant, as disclosed in Curis Inc.'s 2019 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 21, 2019, contingent upon shareholder approval of an amendment to Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the amendment to the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 23, 2019, at the 2019 annual meeting of shareholders, Curis's shareholders approved the amendment to the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 21, 2020 and as to an additional 6.25% of the original shares each successive quarter and until January 21, 2023.

SEC source: 0001209191-19-005357 · doc4.xml · nonDerivative · entry 2

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,639

F1 · kind: These transactions were effected pursuant to Rule 10b5-1 trading plans to cover tax obligations.

F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.17, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4.

F2 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-19-005357 · doc4.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,733

F1 · kind: These transactions were effected pursuant to Rule 10b5-1 trading plans to cover tax obligations.

F2 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001209191-18-052464 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common stock · 750,000 shares

Expires 2028-09-25

F1 · derivative.exercise_date: This option vests as to 25% of the shares on September 26, 2019 and as to an additional 6.25% of the original shares each successive three month period through and until September 26, 2022.

SEC source: 0001209191-18-030871 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · COO & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 825,000

Underlying: Common stock · 825,000 shares

Expires 2028-01-21

F1 · date: This option grant, as disclosed in Curis Inc.'s 2018 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 22, 2018, contingent upon shareholder approval of Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 15, 2018, at the 2018 annual meeting of shareholders, Curis's shareholders approved the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 22, 2019 and as to an additional 6.25% of the original shares each successive quarter and until January 22, 2022.

F1 · derivative.exercise_date: This option grant, as disclosed in Curis Inc.'s 2018 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 22, 2018, contingent upon shareholder approval of Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 15, 2018, at the 2018 annual meeting of shareholders, Curis's shareholders approved the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 22, 2019 and as to an additional 6.25% of the original shares each successive quarter and until January 22, 2022.

SEC source: 0001209191-18-005136 · doc4.xml · nonDerivative · entry 1

Dentzer James E · CIK 0001400977 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,011

F1 · shares: This award is in the form of restricted common stock. The award vests as to 25% of the underlying shares on the first anniversary of the date of grant and as to an additional 25% of the underlying shares annually thereafter.

F2 · balance_after: Represents 5,761 shares of unrestricted common stock acquired under Curis, Inc.'s Amended and Restated 2010 Employee Stock Purchase Plan and 206,250 shares of restricted common stock.

SEC source: 0001209191-17-011475 · doc4.xml · derivative · entry 1

Dentzer James E · CIK 0001400977 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common stock · 650,000 shares

Expires 2027-02-13

F1 · derivative.exercise_date: This option vests as to 25% of the shares on January 1, 2018 and as to an additional 6.25% of the original shares each successive three month period through and until January 1, 2021.